9/7/2023

Sulfasalazine Enteric-Coated and Immediate-Release Tablets

Products Affected - Description

- Sulfasalazine tablet, Teva, 500 mg, bottle, 100 count, NDC 00093-3234-01
- Sulfasalazine tablet, Teva, 500 mg, bottle, 500 count, NDC 00093-3234-05
- Sulfasalazine tablet, Teva, 500 mg, bottle, 1000 count, NDC 00093-3234-10

Reason for the Shortage

- Viatris did not provide a reason for the shortage.
- Teva did not provide a reason for the shortage.
- Pfizer has Azulfidine and Azulfidine Entabs available.

Available Products

- Azulfidine Entabs coated tablet, Pfizer, 500 mg, bottle, 100 count, NDC 00013-0102-50
- Azulfidine Entabs coated tablet, Pfizer, 500 mg, bottle, 300 count, NDC 00013-0102-60
- Sulfasalazine coated tablet, Greenstone (Viatris), 500 mg, bottle, 100 count, NDC 59762-0104-05
- Sulfasalazine coated tablet, Greenstone (Viatris), 500 mg, bottle, 300 count, NDC 59762-0104-06
- Azulfidine tablet, Pfizer, 500 mg, bottle, 100 count, NDC 00013-0101-10
- Azulfidine tablet, Pfizer, 500 mg, bottle, 300 count, NDC 00013-0101-30
- Sulfasalazine tablet, Greenstone (Viatris), 500 mg, bottle, 100 count, NDC 59762-5000-05
- Sulfasalazine tablet, Greenstone (Viatris), 500 mg, bottle, 300 count, NDC 59762-5000-06

Estimated Resupply Dates

- Teva has sulfasalazine immediate-release 500 mg tablets in 100 count, 500 count, and 1,000 count bottles on back order and the company estimates a release date of September 2023.

Updated

Updated September 7, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 8, 2020 by Rachael Freeman, PharmD, BCPS. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.